CN112533643A - 外排体用于靶向递送治疗剂的用途 - Google Patents

外排体用于靶向递送治疗剂的用途 Download PDF

Info

Publication number
CN112533643A
CN112533643A CN201980034058.9A CN201980034058A CN112533643A CN 112533643 A CN112533643 A CN 112533643A CN 201980034058 A CN201980034058 A CN 201980034058A CN 112533643 A CN112533643 A CN 112533643A
Authority
CN
China
Prior art keywords
exosomes
cancer
protein
disorder
disease
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201980034058.9A
Other languages
English (en)
Chinese (zh)
Inventor
拉古·卡尔卢里
瓦莱丽·勒布勒
佩德罗·科雷亚德桑帕约
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Texas System
Original Assignee
University of Texas System
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Texas System filed Critical University of Texas System
Publication of CN112533643A publication Critical patent/CN112533643A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0008—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/45—Transferases (2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/465—Hydrolases (3) acting on ester bonds (3.1), e.g. lipases, ribonucleases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/111—General methods applicable to biologically active non-coding nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C12N2320/32—Special delivery means, e.g. tissue-specific

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
CN201980034058.9A 2018-03-28 2019-03-28 外排体用于靶向递送治疗剂的用途 Pending CN112533643A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862649057P 2018-03-28 2018-03-28
US62/649,057 2018-03-28
PCT/US2019/024603 WO2019191444A1 (en) 2018-03-28 2019-03-28 Use of exosomes for targeted delivery of therapeutic agents

Publications (1)

Publication Number Publication Date
CN112533643A true CN112533643A (zh) 2021-03-19

Family

ID=68060505

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201980034058.9A Pending CN112533643A (zh) 2018-03-28 2019-03-28 外排体用于靶向递送治疗剂的用途

Country Status (7)

Country Link
EP (1) EP3773747A4 (ko)
JP (1) JP2021519296A (ko)
KR (1) KR20200136978A (ko)
CN (1) CN112533643A (ko)
AU (1) AU2019243179A1 (ko)
CA (1) CA3095136A1 (ko)
WO (1) WO2019191444A1 (ko)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT201900007785A1 (it) * 2019-05-31 2020-12-01 Univ Degli Studi Milano Vescicole extracellulari per veicolare farmaci terapeutici o diagnostici
KR20220124170A (ko) * 2019-12-05 2022-09-13 더 보드 오브 리젠츠 오브 더 유니버시티 오브 텍사스 시스템 간 섬유증 및 섬유증 관련 기타 질환에 대한 엑소좀 기반 치료요법
WO2021119552A1 (en) * 2019-12-13 2021-06-17 Lawrence Livermore National Security, Llc Nanotube-vesicle compositions and uses thereof
CN114774471A (zh) * 2022-05-10 2022-07-22 厦门星际诺康细胞科技有限公司 一种呈现il27稳转细胞及其构建方法、呈现il27工程化外泌体及其制备方法和应用

Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070259814A1 (en) * 2004-10-14 2007-11-08 Lynch Samuel E Platelet Derived Growth Factor and Methods of Use Thereof
US20140348904A1 (en) * 2011-12-07 2014-11-27 Isis Innovation Limited Exosomes With Transferrin Peptides
WO2015085096A1 (en) * 2013-12-04 2015-06-11 Board Of Regents, The University Of Texas System Analysis of genomic dna, rna, and proteins in exosomes for diagnosis and theranosis
CN104822390A (zh) * 2012-11-29 2015-08-05 耶达研究及发展有限公司 预防肿瘤转移、癌症治疗和预后及鉴定为推定转移抑制剂的试剂的方法
CN105051192A (zh) * 2012-11-13 2015-11-11 扬·洛特温尔 治疗剂的递送
WO2016201323A1 (en) * 2015-06-10 2016-12-15 Board Of Regents, The University Of Texas System Use of exosomes for the treatment of disease
WO2017117585A1 (en) * 2015-12-30 2017-07-06 The Regents Of The University Of California Methods for enhanced production and isolation of cell-derived vesicles
US20170258938A1 (en) * 2006-05-03 2017-09-14 Codiak Biosciences, Inc. Exosome transfer of nucleic acids to cells
US20180010133A1 (en) * 2016-07-11 2018-01-11 National Health Research Institutes Method of producing exosomes from stem cells and use thereof

Patent Citations (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070259814A1 (en) * 2004-10-14 2007-11-08 Lynch Samuel E Platelet Derived Growth Factor and Methods of Use Thereof
US20170258938A1 (en) * 2006-05-03 2017-09-14 Codiak Biosciences, Inc. Exosome transfer of nucleic acids to cells
US20140348904A1 (en) * 2011-12-07 2014-11-27 Isis Innovation Limited Exosomes With Transferrin Peptides
CN105051192A (zh) * 2012-11-13 2015-11-11 扬·洛特温尔 治疗剂的递送
CN104822390A (zh) * 2012-11-29 2015-08-05 耶达研究及发展有限公司 预防肿瘤转移、癌症治疗和预后及鉴定为推定转移抑制剂的试剂的方法
WO2015085096A1 (en) * 2013-12-04 2015-06-11 Board Of Regents, The University Of Texas System Analysis of genomic dna, rna, and proteins in exosomes for diagnosis and theranosis
WO2016201323A1 (en) * 2015-06-10 2016-12-15 Board Of Regents, The University Of Texas System Use of exosomes for the treatment of disease
CN107980004A (zh) * 2015-06-10 2018-05-01 得克萨斯州大学系统董事会 用于医治疾病的外泌体的用途
WO2017117585A1 (en) * 2015-12-30 2017-07-06 The Regents Of The University Of California Methods for enhanced production and isolation of cell-derived vesicles
US20180010133A1 (en) * 2016-07-11 2018-01-11 National Health Research Institutes Method of producing exosomes from stem cells and use thereof

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
SHIN-ICHIRO OHNO ET AL.: "Systemically Injected Exosomes Targeted to EGFR Deliver Antitumor MicroRNA to Breast Cancer Cells", 《MOLECULAR THERAPY》 *
SHIN-ICHIRO OHNO ET AL.: "Systemically Injected Exosomes Targeted to EGFR Deliver Antitumor MicroRNA to Breast Cancer Cells", 《MOLECULAR THERAPY》, 2 October 2012 (2012-10-02) *

Also Published As

Publication number Publication date
WO2019191444A1 (en) 2019-10-03
EP3773747A1 (en) 2021-02-17
AU2019243179A1 (en) 2020-11-12
CA3095136A1 (en) 2019-10-03
JP2021519296A (ja) 2021-08-10
KR20200136978A (ko) 2020-12-08
EP3773747A4 (en) 2022-02-23

Similar Documents

Publication Publication Date Title
US20200200755A1 (en) Analysis of genomic dna, rna, and proteins in exosomes for diagnosis and theranosis
JP2024023853A (ja) 疾患の処置のためのエキソソームの使用
CN112533643A (zh) 外排体用于靶向递送治疗剂的用途
EP3647421A1 (en) Using minivectors to treat ovarian cancer
US20210038732A1 (en) Anticancer microrna and lipid formulations thereof
JP2024059816A (ja) エキソソーム関連遺伝子編集を用いてがんを処置するための方法および組成物
US20210369858A1 (en) Use of exosomes for targeted delivery of therapeutic agents
US20200197306A1 (en) Cationic liquid crystalline nanoparticles
US20210115449A1 (en) Therapeutic modulation of tumor suppressors using exosomes
CN112236130A (zh) 使用外排体对癌基因的治疗性靶向

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination